Skip to main content Skip to navigation
BUV395 Rat Anti-Mouse CD49d
BUV395 Rat Anti-Mouse CD49d
Flow cytometric analysis using BD OptiBuild™ BUV395 Rat Anti-Mouse CD49d antibody (Cat. No. 745662; solid line histogram) on BALB/c mouse splenocytes, with Isotype Control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.
Flow cytometric analysis using BD OptiBuild™ BUV395 Rat Anti-Mouse CD49d antibody (Cat. No. 745662; solid line histogram) on BALB/c mouse splenocytes, with Isotype Control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
Integrin α4; Itga4; Integrin alpha-4; LPAM alpha; VLA-4 alpha; VLA-4a
Mouse (Tested in Development)
Rat LEW, also known as Lewis IgG2a, κ
Mouse (C57BL/6xA/J)F[1] Fetal Liver Mast MC/9
Flow cytometry (Qualified)
0.2 mg/ml
16401
AB_2743153
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV395 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 395 is covered by one or more of the following US patents: 8,158,444; 8,575,303; 8,354,239.
745662 Rev. 2
Antibody Details
Down Arrow Up Arrow
9C10(MFR4.B)

The 9C10 (MFR4.B) monoclonal antibody specifically binds to the Integrin α4 chain (CD49d), which is expressed as a heterodimer with either of two β chains, β1 or β7. The α4β1 integrin (VLA-4, CD49d/CD29) is expressed on most peripheral lymphocytes, thymocytes, and monocytes; while the α4β7 integrin (LPAM-1) is expressed on peripheral lymphocytes, but on only a small subset of thymocytes. These integrins mediate a variety of cell-cell and cell-matrix interactions, recognizing the ligands VCAM-1 (CD106) and fibronectin. Integrin α4β7 also preferentially binds to the mucosal vascular addressin, MAdCAM-1. Although the 9C10 (MFR4.B) antibody alone has been reported to have little function-blocking activity, it can augment the inhibitory effects of mAb R1-2 (Cat. No. 553153), resulting in almost complete inhibition of VLA-4 binding to VCAM-1.

The antibody was conjugated to BD Horizon™ BUV395 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye has been exclusively developed by BD Biosciences to have minimal spillover into other detectors, making it an optimal choice for multicolor flow cytometry. With an Ex Max at 348 nm and an Em Max at 395 nm, BD Horizon BUV395 can be excited with a 355 nm laser and detected with a 379/28 filter.

745662 Rev. 2
Format Details
Down Arrow Up Arrow
BUV395
The BD Horizon Brilliant™ Ultraviolet 395 (BUV395) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This base dye is a polymer fluorochrome with an excitation maximum (Ex Max) of 348-nm and an emission maximum (Em Max) at 395-nm. Driven by BD innovation, BUV395 is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 380-nm (e.g., 379/28-nm bandpass filter). BUV395 is the ideal dye when using only one detector on the ultraviolet laser as it spills into no other detectors and no other fluors spill into it. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BUV395
Ultraviolet 355 nm
348 nm
395 nm
745662 Rev.2
Citations & References
Down Arrow Up Arrow

Development References (2)

  1. Kinashi T, Springer TA. Adhesion molecules in hematopoietic cells. Blood Cells. 1994; 20(1):25-44. (Immunogen). View Reference
  2. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994; 76(2):301-314. (Biology). View Reference
745662 Rev. 2

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.